GRI Bio announced that the Canadian Intellectual Property Office has issued a notice of allowance for Patent Application No. 3,007,970 titled, “Prevention and Treatment of Inflammatory Conditions.” A patent from the recently allowed application is expected to be issued in the coming months. When issued, the patent will cover claims including compositions and methods for modulating type 2 and/or type 1 invariant NKT cells in the prevention and treatment of inflammatory conditions of the liver. More specifically, when issued the patent will cover the prevention and treatment of inflammatory and fibrotic conditions through the administration of a Retinoic Acid Receptor agonist that inhibits iNKT cells and the administration of an RAR agonist that inhibits the activity of iNKT cells in a subject.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GRI:
- GRI Bio receives MRHA authorization to conduct Phase 2a study of GRI-0621
- GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom
- GRI Bio Announces Offering Pricing Details
- GRI Bio Launches Major Securities Public Offering
- GRI Bio Announces Pricing of $5.5 Million Public Offering